1. SO-010Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors. (2nd July 2019) Authors: Garralda, E; Fiedler, W; Matos, I; Rolling, C; Kebenko, M; Klinghammer, K; Conte, G; Raspagliesi, F; Habel, B; Baumeister, H; Ochsenreither, S; Zurlo, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 427PPhase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma. (23rd October 2018) Authors: Moek, K L; Fiedler, W M; von Einem, J C; Verheul, H M; Seufferlein, T; de Groot, D J; Heinemann, V; Kebenko, M; Menke-van der Houven van Oordt, C W; Ettrich, T J; Rasmussen, E; Bogner, P; Sable, B; Stienen, S; de Vries, E G E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1510TiPThe GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors. (23rd October 2018) Authors: Garralda, E; van Hoef, M; Ochsenreither, S; Gianni, L; Lorusso, D; Fiedler, W; Keilholz, U; Klinghammer, K; Dicke, C; Kebenko, M; Matos, I; Tabernero, J; Raspagliesi, F; Del Conte, G; Habel, B; Baumeister, H; Zurlo, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗